XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 4 Months Ended 9 Months Ended
Jun. 03, 2024
Feb. 01, 2024
Sep. 30, 2022
Jul. 31, 2024
Feb. 29, 2024
Apr. 30, 2023
Sep. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Mar. 01, 2021
Payments of Debt Restructuring Costs               $ 21,179 $ (0)  
Cash, Cash Equivalents, and Short-Term Investments             $ 123,200 123,200    
Net Cash Provided by (Used in) Operating Activities               119,823 $ (109,551)  
Equity Offering Facility, Maximum Aggregate Offering Amount                   $ 150,000
Charge for Delivery of Narsoplimab Drug Substance [Member]                    
Other Nonrecurring Expense               $ 18,400    
Conversion of 2026 Notes into New Term Loans [Member]                    
Payments of Debt Restructuring Costs $ 21,200     $ 600     $ 21,200      
Debt Conversion, Original Debt, Amount $ 118,100                  
Debt Instrument, Interest Rate, Stated Percentage 5.25%                  
Debt Instrument, Increase (Decrease), Net $ 51,000                  
The Credit and Guaranty Agreement [Member]                    
Line of Credit Facility, Maximum Borrowing Capacity 92,100                  
Debt Instrument, Interest Rate, Stated Percentage             13.87% 13.87%    
Debt Instrument, Covenant, Required Unrestricted Cash 25,000           $ 25,000 $ 25,000    
The Credit and Guaranty Agreement [Member] | Delayed Draw Term Loan (DDTL) [Member]                    
Line of Credit Facility, Maximum Borrowing Capacity 25,000                  
Debt Instrument, Face Amount $ 25,000                  
Debt Instrument, Notice for Withdrawal Period 30 days                  
The Credit and Guaranty Agreement [Member] | Initial Term Loan [Member]                    
Debt Instrument, Face Amount $ 67,100                  
DRI Healthcare Acquisition LP [Member]                    
Proceeds From Royalty Obligation   $ 115,500 $ 125,000   $ 115,500          
PDE7 [Member] | National Institute on Drug Abuse ("NIDA") [Member]                    
Grants Receivable           $ 6,690        
Grants Receivable, Period           3 years        
Revenue from Contract with Customer, Excluding Assessed Tax           $ 1,000        
Other Income           $ 800